Answer
Aromasin (exemestane) is indicated for advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy; efficacy has not been demonstrated in patients with oestrogen receptor-negative status.
Sources for this answer
- AromasinPfizer Limited · emc · SmPC §4.1 Therapeutic Indications · Version 22Document updated
Sources checked